Neuprex recombinant bactericidal/permeability-increasing protein regulatory update

XOMA said the FDA determined that data from XOMA's Phase III trial of Neuprex to treat meningococcemia were not sufficient to support the filing of a BLA. The data, reported by XOMA and partner BAX fr...